Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the stock.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, JMP Securities cut their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Stock Up 0.9 %

Structure Therapeutics stock opened at $33.55 on Wednesday. The company’s 50-day moving average price is $37.66 and its 200-day moving average price is $39.38. Structure Therapeutics has a twelve month low of $26.61 and a twelve month high of $64.45. The company has a market cap of $1.92 billion, a PE ratio of -45.34 and a beta of -3.41.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares during the period. FMR LLC boosted its position in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after buying an additional 383,635 shares during the period. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares during the period. Driehaus Capital Management LLC boosted its position in Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after buying an additional 86,833 shares during the period. Finally, Federated Hermes Inc. boosted its position in Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.